-
Recent Posts
Archives
Categories
Meta
The Book
-
-
Join 8 other subscribers
Category Archives: Investor
Pharma Mergers and Acquisitions: No-win or a No-Lose Propositions
This seems to be the season for mergers and acquisitions in Pharma. What is the motivation for these transactions. One possibility is that if structured correctly, a merger or acquisition can be a no-lose proposition for accounting purposes and a … Continue reading
Posted in Biotech, Investor, Layoffs, Mergers, New drug development, Pharmaceutical Companies, R&D Productivity
Tagged biotechnology and pharmaceuticals, Drug Development, GAAP, Generally Accepted Accounting Principles, Mergers and acquisitions, Pharmaceutical Industry, pharmaceutical investing, pharmaceutical investment, Rate of return, Research and development
1 Comment
Changes at Merck
As I have written in this blog for the last couple of years and talked about for many years, the path to success in the pharmaceutical industry is clear and relatively straightforward. The problem is that many managers find … Continue reading
Some Good News
The trend of falling R&D productivity in the pharmaceutical industry seems to be reversing. As shown in the following Figure, the number of new chemical entity approvals in 2011 and 2012 have increased above those for the last 7 years. … Continue reading
Alzheimer’s Tragedy
Alzheimer’s disease is a tragic condition. It slowly robs a person of their most precious possession, consciousness. However, these days, that’s not the only tragic aspect of Alzheimer’s disease. There is an ongoing tragic misallocation of research resources. As long … Continue reading
Bye Bye Pfi
In my book, published about 2 years ago, I outlined why generally accepted accounting practices (GAAP), at least as commonly implemented, often don’t capture the reality of pharma company profits and losses in a common sense way. For example, if … Continue reading
Resolving Controversies on the Path to Alzheimer’s Disease Therapeutics
The Alzheimer’s research forum is a nice way of keeping track of the mainstream of Alzheimer’s disease research, especially since it is free and open to anyone. I think the recent Webinar entitled “Resolving Controversies on the Path to AD … Continue reading
Pharma Mergers Adversely Affect R and D
There was a recent Letter in Nature Reviews, Drug Discovery suggesting mergers have an adverse effect on pharmaceutical R&D. It’s great to see that the effects of mergers on pharma R and D productivity are finally getting some attention. The Letter received coverage … Continue reading
Over Concentration in The Current Direction of Alzheimer’s Disease Clinical Trials?
A recent email from the Alzforum described a meeting in Sweden on the immunotherapy of Alzheimer’s disease. As described in this email, there are at least 40 ongoing studies of immune therapies which I assume are mainly directed at removal of various … Continue reading
NCDEU Meeting continued…
Some interesting conversations at the NCDEU Meeting. One of my more interesting conversations was with a professor from a prominent business school. When I challenged the high number for the cost of a new drug approval he quoted, he told … Continue reading
Revenge of the (Laid Off) Nerds
Everyone in the pharmaceutical business is aware of the trend toward ‘consolidation’. I think this is really a misnomer because typically the companies are not ‘consolidated’ into one continuing organization. In my experience what happens is that the acquiring company … Continue reading
The Book - New Drugs: An Insider's Guide to the FDA's New Drug Approval Process, For Scientists, Investors and Patients 